Though relapsing-remitting multiple sclerosis, or RRMS, can be managed with many of the approved treatments for MS symptoms, there is still no scientifically proven, FDA-cleared way to predict when or ...

A blood-based biomarker assay for multiple sclerosis (MS) disease activity provides actionable insights that supplement standard MS evaluations, especially for treatment initiation and de-escalation ...

Researchers have created a blood test to detect multiple sclerosis (MS) patients' immunological responses, which may help us understand and treat the disease. Around 2.8 million individuals worldwide ...

Siemens Healthineers has inked what it describes as a “master collaboration agreement” with Novartis to help provide diagnostic tests linked to therapies across the drugmaker’s pipeline. To start, the ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation to the Elecsys Neurofilament Light Chain (NfL) test for multiple sclerosis (MS). Made by Roche, the test is ...

The U.S. FDA granted Roche Holding AG breakthrough device designation for its Elecsys Neurofilament Light Chain test for multiple sclerosis. The Elecsys NfL test can aid in the detection of disease ...

MYND Diagnostics will be initiating a clinical validation study on the use of its proprietary biomarker testing in Multiple Sclerosis diagnostics "According to the National Multiple Sclerosis Society, ...

A research team at the Medical University of Vienna has developed a blood test that allows the identification of individuals at risk for developing multiple sclerosis (MS) with a high degree of ...

Serum neurofilament light chain (NfL) elevation -- a sign of accelerated neuroaxonal injury -- appeared about 1 year before disability worsening events associated with relapses in multiple sclerosis ...

Share on Pinterest Scientists are trying to find blood biomarkers that may help predict the course of disease in MS. Betsie Van der Meer/Getty Images As of 2020, about 2.8 million people globally have ...

The diagnostic criteria for MS reflect a growing understanding of the condition and the application of new advancements in medical technology to help improve diagnostic accuracy and reliability.